Therapeutic potential of mycobacterial cell wall-DNA complexes

Expert Opinion on Investigational Drugs

Volumn 10, Issue 12, 2001, Pages 2157-2165

  Filion, M C ^a   Phillips, N C ^a  

^a Bioniche Therapeutics Research Centre   (Canada)

Author keywords

Apoptosis; Bladder; Cancer; Immunomodulation; Mycobacteria; Oligonucleotide prostate

Indexed keywords

BACTERIAL DNA; BCG VACCINE; CELL WALL SKELETON; CISPLATIN; CYTOKINE; MITOMYCIN C; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL; CELL ACTIVATION; CELL DIVISION; CELL WALL; CHEMICAL COMPOSITION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TOLERABILITY; EXTRACT; FEMALE; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM PHYLEI; NONHUMAN; PROSTATE CANCER; REVIEW; SEPSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS; BIOLOGICAL PRODUCTS; CELL WALL; DNA, BACTERIAL; HUMANS; MALE; MYCOBACTERIUM; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0035218319     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.12.2157     Document Type: Review

References (95)

1. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)
2. Safety and efficacy of living BCG or BCG cell walls (CW) in the treatment of guinea pig hepatoma
3. Immunotherapy of cancer: Tumour suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets
4. Mycobacterium cell wall: An alternative to intravesical bacillus Calmette Guérin (BCG) therapy in orthotopic murine bladder cancer
5. Intralesional immunotherapy of malignant melanoma with Mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3)
6. Immunotherapy with nonviable microbial components
7. Adjuvant and antitumour activities of Nocardia cell wall skeleton
8. Randomised clinical trial of non-specific immunotherapy with cell-wall skeleton of Nocardia rubra
9. A new morphogically characterised cell wall preparation (whole peptidoglycan) from Bifidobacterium infantis with a higher efficacy on the regression of an established tumour in mice
10. Adjuvants for a tumour-specific vaccine: Bordetella pertussis or mycobacterial cell walls attached to oil droplets
11. Therapeutic effect of cell wall skeleton of Propionibacterium acnes in combination with a monoclonal antibody (C6-1.2) on the lung metastases of Lewis lung carcinoma
12. Antitumour activity of bacterial fractions and related synthetic compounds
13. Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: A preliminary report
14. Augmentative effect of Nocardia rubra cell wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction
15. Does the cell wall skeleton from Bacille Calmette-Guérin induce interferon-gamma, independent of interleukin-12?
16. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy - A Phase I/II study
17. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: Involvement of toll-like receptor
18. Potential use of muramyl peptides in cancer therapy
19. Tumour regression after intralesional injection of mycobacterial components emulsified in 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (squalene), peanut oil, or mineral oil
20. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure
21. Macrophage inflammatory protein-1 alpha expression in vivo and in vitro: The role of lipoteichoic acid
22. Antitumour and antimetastatic activity of the immunoadjuvant peptidolgycan monomer PGM in mice bearing Mca mammary carcinoma
23. An antineoplastic glycan isolated from Mycobacterium bovis (BCG vaccine)
24. Environmental mycobacteria in bottled table waters in Greece
25. Search for acid-fast bacilli in bottled mineral waters
26. Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria
27. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex
28. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeleton (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: A comparative study
29. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells
30. Pro-apoptotic and immunotherapeutic activity of a mycobacterial cell wall-DNA complex preparation (MCC)
31. Eradication of murine bladder carcinoma by intratumour injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
32. Synergistic antitumour effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model
33. Interleukin-12 an integral cytokine in the immune response
34. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumour immunity
35. Tumour-induced immune dysfunction
36. The effects of therapeutic irradiation on lymphocytes and immunity
37. Can cancer chemotherapy enhance the malignant behaviour of tumours
38. How much longer will tumour cells fool the immune system
39. Mycobacterial cell wall-DNA complex induces apoptosis in cancer cells
40. Mycobacterial DNA induces apoptosis in myeloid leukaemia cell lines
41. Mycobacterial DNA induces apoptosis in tumour cells
42. Mycobacterial cell wall-DNA complex (MCC) inhibits proliferation and induces apoptosis in androgen-dependent and independent human prostate cancer cells
43. Cell death: The significance of apoptosis
44. Apoptosis in the pathogenesis and treatment of disease
45. Apoptosis and therapy
46. Apoptosis in cancer
47. Mitochondrial and apoptosis
48. Mitochondria as the central control point of apoptosis
49. Investigation of glucocorticoid-induced apoptotic pathway: Processing of caspase-6 but not caspase-3
50. Antitumour activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterisation, and antitumour activity
51. Antitumour activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic tumours
52. In vivo augmentation of natural killer activity with a deoxyribonucleic acid fraction of BCG
53. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumour growth
54. Antitumour activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG
55. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids towards immune effector cells
56. Mycobacterium phlei cell-wall complex, a new antitumoural agent, induces IL-12 synthesis by monocyte-macrophages via associated DNA
57. CpG motifs in bacterial DNA trigger direct B-cell activation
58. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma
59. Macrophages sense pathogens via DNA motifs: Induction of tumour necrosis factor-alpha-mediated shock
60. Base composition of deoxyribonucleic acid isolated from mycobacteria
61. Contribution of CpG motifs to the immunogenecity of DNA vaccines
62. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukaemia B cells
63. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL
64. DNA isolated from Mycobacterium phlei has the ability to induce apoptosis in leukaemia cells
65. Morphologic expressions of urothelial carcinoma in situ: A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion
66. BCG immunotherapy of bladder cancer: 20 years on
67. Long term follow-up of intravesical Bacillus Calmette-Guérin for the treatment of bladder transitional cell carcinoma
68. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer
69. Biological response modifiers for the treatment of superficial bladder tumours
70. Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro?
71. Intravesical bacillus Calmette-Guérin (BCG) as inducer of tumour suppressing proteins p53 and p21 Waf1-Cip1 during treatment of superficial bladder cancer
72. Abrogation of apoptosis induced by DNA-damaging agents in human bladder cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations
73. Doxorubicin sensitises human bladder carcinoma cells to Fas-mediated cytotoxicity
74. p53 in bladder cancer: Mechanism of cation, prognostic value, and target for therapy
75. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: Correlation to clinical outcome
76. p53 mutations in bladder tumours inactivate the transactivation of the p21 and Bax genes and have predictive value for the clinical outcome after bacillus Calmette-Guérin therapy
77. Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer
78. Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers
79. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
80. Macrophage role in the anti-prostate cancer response to one class of anti-angiogenic agents
81. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
82. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
83. Predictors of improved outcome for patients with localised prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy
84. Immunotherapy of Prostatic cancer with BCG and purified protein derivative
85. Adjuvant immunotherapy with BCG in carcinoma of the prostate
86. Induction of controlled prostatic tissue necrosis by Bacille Calmette-Guérin derivatives
87. Mycobacterium vaccae (SRL 172): A potential immunological adjuvant evaluated in rat prostate cancer
88. A fresh look at tumour immunosurveillance and immunotherapy
89. Apoptosis in cancer: Cause and cure
90. Phase I study of iv. mycobacterial cell wall skeleton and cell wall skeleton combined with trehalose dimycolate
91. BCG-cell wall skeleton completely cures the immunologically eligible acute leukaemia patients
92. Inhibition of cell cycle progression and induction of apoptosis in leukaemia cells by Mycobacterium phlei DNA and derived synthetic oligonucleotides
93. Pro-apoptotic activity of non-CpG motif containing oligonucleotides towards leukaemia cells
94. Stimulation of cytokine synthesis in human and primate peripheral blood mononuclear cells by non-CpG motif oligonucleotides
95. Pro-apoptotic and immunomodulatory activity of a mycobacteril cell wall-DNA complex towards LNCaP prostate cancer cells